Giulia Marchetti
COVID-19 from immunepathogenesis to therapy
Materiali
COVID-19 from immunepathogenesis to therapy
Immune responses to SARS-CoV-2 natural infection and vaccination in people
Efficacy and virological clearance of antivirals/monoclonals in high-risk patients
Prevalence, phenotypes and predictive factors of PASC in the Eucare cohort
Immunepathogenesis of PASC
Microbiome Immunity and Diet in the development of pASC: MIDAS study
The gut as a site of immunepathogenesis
Effects of cART on residual inflammation and HIV reservoirs in Primary and Chronic HIV infection
Study of the gastrointestinal tract in acute HIV infection
New antiretrovirals for HIV: real-life experience with doravirine
Switching to Long-Acting Injectable Antiretroviral Therapy: experience from our Clinic
HBcAb positivity on two-drug regimens in SPID: evidence of HBV reactivation?
High Prevalence of HIV Infection and Late Diagnoses by HIV indicator conditions guided screening in the Emergency Department: preliminary results from INDI study
Sexually Transmitted Infections In A Northern Italy Sti Clinic: results of the SECS study
/assets/17-10-Tesoro.pdf
IcoNA overview
Patient-related outcomes (PROs)
Long-acting and Outpatient Parenteral Antimicrobial Therapy (OPAT): challenges and opportunities
Superinfections in patients on invasive and non-invasive ventilation during Covid-19: prevalence, predictive factors and mortality
Predictors of treatment choice in the management of ABSSSIs (Dalbavancin versus SoC)
Factors associated with persistent Gram-positive bacteremia
Switch from intravenous to oral antibiotic therapy in the treatment of infective endocarditis: preliminary results and PDTA proposal
CEFI-BAC Study: A Multicentre Observational Study on Cefiderocol for the Treatment of Multi-Drug Resistant Gram-Negative Bacteria (Ongoing Research Update).
Proposal for the implementation of infection prevention and control (IPC) e dell’ antimicrobial stewardship (AMD).